Novo Nordisk A/s

This study tests an experimental medicine called cagrilintide to see if it helps people with overweight or obesity and type 2 diabetes lose weight. About 330 adults will receive either the drug or a placebo for around 18 months. The main goals are to measure how much weight they …

This study tests whether semaglutide, a medicine already used for diabetes, can help people with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 1,200 adults with NASH and liver scarring (but not cirrhosis) will receive weekly injections of semaglutide …

This study follows 1250 people with obesity who are starting Wegovy as part of their regular care. Researchers will track weight, waist size, and quality of life over two years to see how the drug works in everyday life. The goal is to understand real-world effectiveness, not to …

This early-stage study tests a new injectable medicine for people who are overweight or have obesity. The main goal is to check if the medicine is safe and how the body handles it. About 63 participants will receive either the study drug or a placebo injection. This medicine is n…

This study is a registry that will follow up to 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will track how their height changes over time, any side effects, and their quality of life. The goal is to gather real-…

This study follows pregnant women who took Wegovy for obesity or overweight to see if it affects the health of their babies. Researchers will compare these women to similar pregnant women who did not take Wegovy. The goal is to learn about any birth defects or other health issues…